Jefferies (NYSE:JEF) analyst Stephanie Wissink maintained a Hold rating on Prestige Brand Holdings (NYSE:PBH) on Thursday, setting a price target of $54, which is approximately 2.25% above the present share price of $52.81.
Wissink expects Prestige Brand Holdings to post earnings per share (EPS) of $0.71 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Hold rating of shares in Prestige Brand Holdings, with an average price target of $53.
The analysts price targets range from a high of $54 to a low of $52.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $237.76 million and a net profit of $70.94 million. The company's market cap is $2.64 billion.
According to TipRanks.com, Jefferies analyst Stephanie Wissink is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.2% and a 55.48% success rate.
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare, and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.